TODAY’S PATENT – METHYLSULFONYLMETHANE (MSM) FOR TREATMENT OF DRUG RESISTANT MICROORGANISMS
This patent relates to a method of increasing the susceptibility of methicillin-resistant Staphylococcus aureus (MRSA) to beta-lactam antibiotics, which it typically resists. The invention discloses the use of methylsulfonylmethane (MSM) compositions for the treatment of drug-resistant infectious diseases, particularly MRSA. The patent also provides various compositions that are effective in treating MRSA infections.
![TODAY'S PATENT - METHYLSULFONYLMETHANE (MSM) FOR TREATMENT OF DRUG RESISTANT MICROORGANISMS](https://todayspatent.com/wp-content/uploads/sites/6/2023/07/TODAYS-PATENT-METHYLSULFONYLMETHANE-MSM-FOR-TREATMENT-OF-DRUG-RESISTANT-MICROORGANISMS-1-300x257.png)
The inventors of this technique are Rodney Benjamin, Jeffrey Varelman, and Anthony Keller. It received a patent from USPTO on 10th July 2012 bearing the serial number US8217085B2. The invention involves sensitizing drug-resistant microbes to beta-lactam antibiotics by using MSM. This is a significant breakthrough in the field of medicine as MRSA is a notorious drug-resistant bacterium that has caused many healthcare-associated infections. The use of MSM compositions as described in this patent provides a new approach to treating MRSA infections and other drug-resistant infectious diseases.
The patent is a valuable contribution to the field of medicine and offers new treatment options for drug-resistant infections. The invention has the potential to save many lives and improve healthcare outcomes by providing a more effective way of treating MRSA and other drug-resistant infectious diseases.